DK1355646T3 - Muscariniske receptoragonister - Google Patents

Muscariniske receptoragonister

Info

Publication number
DK1355646T3
DK1355646T3 DK01995477T DK01995477T DK1355646T3 DK 1355646 T3 DK1355646 T3 DK 1355646T3 DK 01995477 T DK01995477 T DK 01995477T DK 01995477 T DK01995477 T DK 01995477T DK 1355646 T3 DK1355646 T3 DK 1355646T3
Authority
DK
Denmark
Prior art keywords
receptor agonists
muscarinic receptor
independently selected
orand
coch3
Prior art date
Application number
DK01995477T
Other languages
English (en)
Inventor
William S Messer
Yang Cao
Original Assignee
Univ Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toledo filed Critical Univ Toledo
Application granted granted Critical
Publication of DK1355646T3 publication Critical patent/DK1355646T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01995477T 2001-01-29 2001-12-10 Muscariniske receptoragonister DK1355646T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/772,143 US6376675B2 (en) 1999-01-22 2001-01-29 Muscarinic receptor agonists
PCT/US2001/047474 WO2002060444A1 (en) 2001-01-29 2001-12-10 Muscarinic receptor agonists

Publications (1)

Publication Number Publication Date
DK1355646T3 true DK1355646T3 (da) 2009-08-17

Family

ID=25094053

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01995477T DK1355646T3 (da) 2001-01-29 2001-12-10 Muscariniske receptoragonister

Country Status (9)

Country Link
US (2) US6376675B2 (da)
EP (1) EP1355646B1 (da)
JP (2) JP2004520382A (da)
AT (1) ATE431143T1 (da)
CA (1) CA2434839A1 (da)
DE (1) DE60138732D1 (da)
DK (1) DK1355646T3 (da)
ES (1) ES2327104T3 (da)
WO (1) WO2002060444A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
US8729129B2 (en) 2004-03-25 2014-05-20 The Feinstein Institute For Medical Research Neural tourniquet
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
CN102793972A (zh) 2004-12-27 2012-11-28 范因斯坦医学研究院 通过电刺激迷走神经治疗炎症性疾病
US20090012101A1 (en) * 2005-12-27 2009-01-08 University Of Toledo Mucarinic Agonists and Methods of Use Thereof
WO2008118326A1 (en) * 2007-03-23 2008-10-02 University Of Toledo Muscarinic agonists and methods of use thereof
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US20110294835A1 (en) 2008-05-15 2011-12-01 The Board Of Trustees Of The University Of Illinois Muscarinic Agonists as Cognitive Enhancers
WO2009152392A2 (en) * 2008-06-11 2009-12-17 University Of Toledo Muscarinic agonists for neurological disorders and methods of making the same
ES2452484T3 (es) 2008-11-18 2014-04-01 Setpoint Medical Corporation Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
WO2010144578A2 (en) 2009-06-09 2010-12-16 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
CN105126248B (zh) 2009-12-23 2018-06-12 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
US11406833B2 (en) 2015-02-03 2022-08-09 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
US10314501B2 (en) 2016-01-20 2019-06-11 Setpoint Medical Corporation Implantable microstimulators and inductive charging systems
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
US11173307B2 (en) 2017-08-14 2021-11-16 Setpoint Medical Corporation Vagus nerve stimulation pre-screening test
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
US12343535B2 (en) 2019-04-12 2025-07-01 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
AU2021207815B2 (en) 2020-01-13 2026-03-26 The Feinstein Institutes For Medical Research Treating bleeding and bleeding disorders via high intensity focused ultrasound stimulation of the spleen
US11938324B2 (en) 2020-05-21 2024-03-26 The Feinstein Institutes For Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
US20250229086A1 (en) 2022-01-20 2025-07-17 Setpoint Medical Corporation Treatment of inflammatory disorders
WO2025030095A1 (en) * 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis
WO2025174424A1 (en) * 2024-02-16 2025-08-21 Terran Biosciences Inc. Analogs of xanomeline, analogs of trospium, and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5376668A (en) * 1990-08-21 1994-12-27 Novo Nordisk A/S Heterocyclic compounds
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
WO1993014089A1 (en) 1992-01-13 1993-07-22 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
US5718912A (en) 1996-10-28 1998-02-17 Merck & Co., Inc. Muscarine agonists
US6096767A (en) 1999-01-22 2000-08-01 The University Of Toledo Muscarinic receptor agonists

Also Published As

Publication number Publication date
EP1355646A1 (en) 2003-10-29
US20010036953A1 (en) 2001-11-01
ES2327104T3 (es) 2009-10-26
US20030032658A1 (en) 2003-02-13
CA2434839A1 (en) 2002-08-08
JP2004520382A (ja) 2004-07-08
ATE431143T1 (de) 2009-05-15
US6602891B2 (en) 2003-08-05
WO2002060444A1 (en) 2002-08-08
US6376675B2 (en) 2002-04-23
DE60138732D1 (de) 2009-06-25
JP2010159274A (ja) 2010-07-22
EP1355646B1 (en) 2009-05-13
EP1355646A4 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
DK1355646T3 (da) Muscariniske receptoragonister
EP1423111A4 (en) FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
IL162296A (en) Composition of nanoparticles of antagonist receptor antagonist tachykinin
CA2233285A1 (en) Pyrazolopyrimidines as crf receptor antagonists
MY119118A (en) Thiophenopyrimidines
EA200101223A1 (ru) Новые соединения, их применение и получение
FI905839A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten trisyklisten, typpipitoisten yhdisteiden valmistamiseksi
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
LU91761I2 (fr) Vernakalant et ses dérivés pharmaceutiquement acceptables et en particulier son sel d'hydrochlorure (BRINAVESS®)
MXPA00006605A (es) Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
KR100366902B1 (ko) 섭스턴스 ｐ 길항제로서 피페리디닐아미노메틸트리플루오로메틸 시클릭 에테르 화합물
GEP20084519B (en) 3-(4-heteroarylcyclo-hexylamino) cyclopenta-necarboxamides as modulators of chemokine receptors
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
EA200501593A1 (ru) Азабициклические производные в качестве антагонистов мускаринового рецептора
DE60016786D1 (de) Bicyclische vasopressin-agoniste
BR0006371A (pt) Compostos de 1,4-dihidropiridina substituìdos com heteroarilas de 5 membros como antagonistas de bradicinina
EP1256581A4 (en) PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRICHES OR ESOPHAGEAL REGURGITATION
ATE121732T1 (de) Maleimidverbindungen und diese enthaltende fungizide.
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
EP1253139A3 (en) Multioligoanilinated fullerenes
ATE293591T1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
WO2002017954A1 (fr) Medicaments contre la maladie de parkinson
DE69703725D1 (de) Tetrazolyl-substituierte Chinuclidine als Substanz P Antagonisten
SE9901884D0 (sv) Novel compounds their use and preparation